Skip to content

Long-Term Follow-Up Study of “A Study on Speech Function Improvement in Patients with Post-Stroke Aphasia Following Right C7 neurotomy at the intervertebral foramen: An Exploratory Randomized Controlled Clinical Trial”

Long-Term Follow-Up Study of “A Study on Speech Function Improvement in Patients with Post-Stroke Aphasia Following Right C7 neurotomy at the intervertebral foramen: An Exploratory Randomized Controlled Clinical Trial”

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129477
Enrollment
Unknown
Registered
2026-08-05
Start date
2026-06-17
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Aphasia Following a Stroke

Interventions

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Completed preliminary clinical trials: Patients who participated in the institution-led "Study on Speech Function Improvement Following Right C7 neurotomy at the intervertebral foramen in Patients with Post-Stroke Aphasia: An Exploratory Randomized Controlled Clinical Trial."; 2. Ages 40–70; 3. Informed Consent: I, or my legal guardian, fully understand the purpose and procedures of this long-term follow-up study and voluntarily sign the informed consent form for the long-term follow-up study.

Exclusion criteria

Exclusion criteria: 1. Participants with new-onset severe neurological disorders: Since the conclusion of the previous clinical study, participants who have experienced a new-onset severe traumatic brain injury, a new-onset stroke (ischemic or hemorrhagic), or have been diagnosed with other neurodegenerative diseases (such as Parkinson’s disease, Alzheimer’s disease, etc.), and who, in the investigator’s assessment, are likely to significantly interfere with the results of this language function assessment; 2. Severe, uncontrolled systemic diseases: Participants with severe systemic diseases (such as heart failure, respiratory failure, renal failure, or malignant tumors) or those in extremely poor general condition for any reason, whom the investigator determines are unable to complete the follow-up assessment procedures; 3. New or Changed Contraindications for MRI: The presence or new implantation of any items or conditions contraindicated for magnetic resonance imaging (MRI) (such as a new type of incompatible pacemaker or aneurysm clip implanted in the body, or the onset of claustrophobia), resulting in the inability to complete the neuroimaging examination; 4. Death, voluntary withdrawal, or loss to follow-up: Study participants who die from the disease; who explicitly withdraw their informed consent and request to withdraw from the study; or who cannot be contacted through various means (telephone, mail, home visits, etc.), resulting in the inability to complete follow-up data collection.

Design outcomes

Secondary

MeasureTime frame
fugl-meyer assessment;Range of Motion;Two-Point Discrimination and Tactile Thresholds;Upper Limb Muscle Strength;Western Aphasia Battery (WAB) Mandarin Version;Functional Magnetic Resonance Imaging Scan;

Primary

MeasureTime frame
Boston Naming Test (BNT);

Countries

China

Contacts

Public ContactXu Wendong

Huashan Hospital, Fudan University

wendongxu@fudan.edu.cn+86 21 52888732

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026